These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 20624283)

  • 1. A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients.
    Fardin P; Barla A; Mosci S; Rosasco L; Verri A; Versteeg R; Caron HN; Molenaar JJ; Ora I; Eva A; Puppo M; Varesio L
    Mol Cancer; 2010 Jul; 9():185. PubMed ID: 20624283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Artificial neural network classifier predicts neuroblastoma patients' outcome.
    Cangelosi D; Pelassa S; Morini M; Conte M; Bosco MC; Eva A; Sementa AR; Varesio L
    BMC Bioinformatics; 2016 Nov; 17(Suppl 12):347. PubMed ID: 28185577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The l1-l2 regularization framework unmasks the hypoxia signature hidden in the transcriptome of a set of heterogeneous neuroblastoma cell lines.
    Fardin P; Barla A; Mosci S; Rosasco L; Verri A; Varesio L
    BMC Genomics; 2009 Oct; 10():474. PubMed ID: 19832978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Logic Learning Machine creates explicit and stable rules stratifying neuroblastoma patients.
    Cangelosi D; Blengio F; Versteeg R; Eggert A; Garaventa A; Gambini C; Conte M; Eva A; Muselli M; Varesio L
    BMC Bioinformatics; 2013; 14 Suppl 7(Suppl 7):S12. PubMed ID: 23815266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
    Hallett RM; Seong AB; Kaplan DR; Irwin MS
    Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Attribute Driven Incremental Discretization and Logic Learning Machine to build a prognostic classifier for neuroblastoma patients.
    Cangelosi D; Muselli M; Parodi S; Blengio F; Becherini P; Versteeg R; Conte M; Varesio L
    BMC Bioinformatics; 2014; 15 Suppl 5(Suppl 5):S4. PubMed ID: 25078098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYCN and HIF-1 directly regulate
    Hains AE; Uppal S; Cao JZ; Salwen HR; Applebaum MA; Cohn SL; Godley LA
    Epigenetics; 2022 Dec; 17(13):2056-2074. PubMed ID: 35942521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha.
    Qing G; Skuli N; Mayes PA; Pawel B; Martinez D; Maris JM; Simon MC
    Cancer Res; 2010 Dec; 70(24):10351-61. PubMed ID: 20961996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of multiple hypoxia signatures in neuroblastoma cell lines by l1-l2 regularization and data reduction.
    Fardin P; Cornero A; Barla A; Mosci S; Acquaviva M; Rosasco L; Gambini C; Verri A; Varesio L
    J Biomed Biotechnol; 2010; 2010():878709. PubMed ID: 20652058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
    Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
    Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.
    Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E
    Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of clinical characteristics and molecular signatures of the tumor microenvironment to predict the prognosis of neuroblastoma.
    Cheng H; Zhang L; Yang S; Ren Q; Chang S; Jin Y; Mou W; Qin H; Yang W; Zhang X; Zhang W; Wang H
    J Mol Med (Berl); 2023 Nov; 101(11):1421-1436. PubMed ID: 37712965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical analysis of PDK1, PHD3 and HIF-1α expression defines the hypoxic status of neuroblastoma tumors.
    Ognibene M; Cangelosi D; Morini M; Segalerba D; Bosco MC; Sementa AR; Eva A; Varesio L
    PLoS One; 2017; 12(11):e0187206. PubMed ID: 29117193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.
    Yang XH; Tang F; Shin J; Cunningham JM
    BMC Syst Biol; 2017 Oct; 11(Suppl 5):92. PubMed ID: 28984200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma.
    Manohar CF; Salwen HR; Brodeur GM; Cohn SL
    Genes Chromosomes Cancer; 1995 Nov; 14(3):196-203. PubMed ID: 8589036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome.
    Cornero A; Acquaviva M; Fardin P; Versteeg R; Schramm A; Eva A; Bosco MC; Blengio F; Barzaghi S; Varesio L
    BMC Bioinformatics; 2012 Mar; 13 Suppl 4(Suppl 4):S13. PubMed ID: 22536959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
    Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
    Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of prognostic long noncoding RNAs associated with spontaneous regression of neuroblastoma.
    Meng X; Fang E; Zhao X; Feng J
    Cancer Med; 2020 Jun; 9(11):3800-3815. PubMed ID: 32216054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
    Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
    Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.